Genzyme, sanofi-aventis deal

Genzyme rejected an unsolicited offer from sanofi-aventis to acquire the company for $69 per share in cash, or about $18.5 billion. The

Read the full 222 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE